What question did this study set out to answer?

To evaluate 24-month visual acuity and fluorescein angiographic outcomes of photodynamic therapy with verteporfin in patients with subfoveal choroidal neovascularization caused by age-related macular degeneration.

October 1, 1999Archives of OphthalmologyOpen Access

Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration With Verteporfin

View Full Paper

Ask AI

Bookmark

Discussion

Member takes

Implication

Randomized double-blind trial reveals sustained visual acuity preservation with verteporfin in age-related macular degeneration, highlighting durable benefits for predominantly classic lesions.

Key Points

To evaluate 24-month visual acuity and fluorescein angiographic outcomes of photodynamic therapy with verteporfin in patients with subfoveal choroidal neovascularization caused by age-related macular degeneration.
Two multicenter, double-masked, placebo-controlled, randomized clinical trials conducted across 22 ophthalmology practices in Europe and North America.
Enrolled 609 patients with subfoveal choroidal neovascularization lesions measuring ≤5400 µm and best-corrected visual acuity between 20/40 and 20/200, assigned to verteporfin (n=402) or placebo (n=207).
Follow-up evaluations occurred every 3 months for 24 months with repeat treatment administered for persistent fluorescein leakage, using an intent-to-treat primary outcome of visual acuity loss <15 letters.
At month 24, 53% (213/402) of verteporfin-treated patients lost fewer than 15 letters of visual acuity compared with 38% (78/207) of placebo-treated patients (P < .001).
Among patients with predominantly classic lesions at baseline, 59% (94/159) receiving verteporfin lost fewer than 15 letters compared with 31% (26/83) receiving placebo (P < .001), with no significant difference observed for minimally classic lesions.
Trial completion at month 24 was 87% (351/402) with verteporfin and 86% (178/207) with placebo, with few additional photosensitivity reactions or injection-site complications during year two.

Cite This Study

A 1999 study studied this question.

synapsesocial.com/papers/6a7d091a19a0fc140faa0587 https://doi.org/10.1001/archopht.117.10.1329

View Full Paper

Ask AI

Bookmark

October 1, 1999Archives of OphthalmologyOpen Access

Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration With Verteporfin

View Full Paper

Ask AI

Bookmark

Discussion

Member takes

Implication

Randomized double-blind trial reveals sustained visual acuity preservation with verteporfin in age-related macular degeneration, highlighting durable benefits for predominantly classic lesions.

Key Points

To evaluate 24-month visual acuity and fluorescein angiographic outcomes of photodynamic therapy with verteporfin in patients with subfoveal choroidal neovascularization caused by age-related macular degeneration.
Two multicenter, double-masked, placebo-controlled, randomized clinical trials conducted across 22 ophthalmology practices in Europe and North America.
Enrolled 609 patients with subfoveal choroidal neovascularization lesions measuring ≤5400 µm and best-corrected visual acuity between 20/40 and 20/200, assigned to verteporfin (n=402) or placebo (n=207).
Follow-up evaluations occurred every 3 months for 24 months with repeat treatment administered for persistent fluorescein leakage, using an intent-to-treat primary outcome of visual acuity loss <15 letters.
At month 24, 53% (213/402) of verteporfin-treated patients lost fewer than 15 letters of visual acuity compared with 38% (78/207) of placebo-treated patients (P < .001).
Among patients with predominantly classic lesions at baseline, 59% (94/159) receiving verteporfin lost fewer than 15 letters compared with 31% (26/83) receiving placebo (P < .001), with no significant difference observed for minimally classic lesions.
Trial completion at month 24 was 87% (351/402) with verteporfin and 86% (178/207) with placebo, with few additional photosensitivity reactions or injection-site complications during year two.

Cite This Study

A 1999 study studied this question.

synapsesocial.com/papers/6a7d091a19a0fc140faa0587 https://doi.org/10.1001/archopht.117.10.1329

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark